Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The SOS response is a global regulatory network in bacteria that is activated in response to significant DNA damage, such as that caused by the mutagenic heterocyclic amine Trp-P-1 (3-Amino-1,4-dimethyl-5H-pyrido[4,3-b]indole) (Sugimura et al., 1977, PNAS). This pathway is primarily controlled by two key proteins: LexA, a repressor that keeps SOS genes silenced under normal conditions, and RecA, which senses DNA damage by binding to single-stranded DNA (Baharoglu & Mazel, 2014, Nature Reviews Microbiology). Upon activation, RecA facilitates the autocatalytic cleavage of LexA, leading to the rapid expression of genes involved in DNA repair, cell cycle arrest, and error-prone translesion synthesis (Bell & Kowalczykowski, 2016, Annual Review of Biochemistry). While the SOS response is a survival mechanism, its error-prone nature is a major driver of genetic diversity and the evolution of antibiotic resistance in bacterial populations. Trp-P-1 specifically induces this pathway by forming DNA adducts that stall replication forks, creating the single-stranded DNA gaps required for RecA activation. In drug discovery, components of the SOS response, particularly RecA, are investigated as therapeutic targets to prevent the emergence of resistance and to potentiate the activity of DNA-damaging antibiotics (Nautiyal et al., 2014, Journal of Medicinal Chemistry). Inhibiting this pathway could theoretically suppress the adaptive mutations that allow pathogens to survive clinical treatment.
Inhibition of RecA-mediated LexA cleavage; inhibition of RecA filament formation on single-stranded DNA; blockade of LexA repressor dissociation from operator sites.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SOS response pathway (SOS response).